BR0203886A - Métodos de tratamento e kits compreendendo um secretagogo do hormÈnio do crescimento - Google Patents

Métodos de tratamento e kits compreendendo um secretagogo do hormÈnio do crescimento

Info

Publication number
BR0203886A
BR0203886A BR0203886-2A BR0203886A BR0203886A BR 0203886 A BR0203886 A BR 0203886A BR 0203886 A BR0203886 A BR 0203886A BR 0203886 A BR0203886 A BR 0203886A
Authority
BR
Brazil
Prior art keywords
kits
relates
present
gastrointestinal motility
treatment methods
Prior art date
Application number
BR0203886-2A
Other languages
English (en)
Inventor
Philip Albert Carpino
David Andrew Griffith
John Rochard Neville Hadcock
William Harras Landschulz
Lydia Codetta Pan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0203886A publication Critical patent/BR0203886A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODOS DE TRATAMENTO E KITS COMPREENDENDO UM SECRETAGOGO DO HORMÈNIO DO CRESCIMENTO". A presente invenção refere-se com métodos de tratamento da bulimia nervosa, disfunção erétil masculina, disfunção sexual feminina, câncer da tireóide ou câncer da mama, ou de melhoramento da lesão isquêmica de tecidos nervosos ou musculares. A presente invenção refere-se também a kits que podem ser utilizados no tratamento da bulimia nervosa, disfunção erétil masculina, disfunção sexual feminina, câncer da tireóide ou câncer da mama, ou no melhoramento da lesão isquêmica de tecidos nervosos ou musculares. A presente invenção refere-se também ao aumento da motilidade gastrintestinal após cirurgia e ao aumento da motilidade gastrintestinal em pacientes aos quais tenha sido administrado um agente que diminui a motilidade gastrintestinal.
BR0203886-2A 2001-09-28 2002-09-25 Métodos de tratamento e kits compreendendo um secretagogo do hormÈnio do crescimento BR0203886A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32592101P 2001-09-28 2001-09-28

Publications (1)

Publication Number Publication Date
BR0203886A true BR0203886A (pt) 2003-09-16

Family

ID=23270016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0203886-2A BR0203886A (pt) 2001-09-28 2002-09-25 Métodos de tratamento e kits compreendendo um secretagogo do hormÈnio do crescimento

Country Status (11)

Country Link
US (1) US20030105114A1 (pt)
EP (1) EP1312363A1 (pt)
JP (1) JP2003160508A (pt)
KR (1) KR20030027865A (pt)
CN (1) CN1410059A (pt)
BR (1) BR0203886A (pt)
CA (1) CA2405342A1 (pt)
HU (1) HUP0203243A2 (pt)
IL (1) IL151835A0 (pt)
PL (1) PL356364A1 (pt)
ZA (1) ZA200207677B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
EP1986508B1 (en) * 2006-01-26 2014-05-21 Hill's Pet Nutrition, Inc. Methods and compositions for treating feline hyperthyroidism
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008100448A2 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
WO2009000087A1 (en) * 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US8759289B2 (en) * 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4783532A (en) * 1983-10-28 1988-11-08 Sankyo Company Limited Process for preparing griseolic acid derivatives
JPS6094992A (ja) * 1983-10-28 1985-05-28 Sankyo Co Ltd グリゼオ−ル酸誘導体
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
NO169901C (no) * 1985-04-19 1992-08-19 Sankyo Co Analogifremgangsmaate for fremstilling av griseolsyrederivater
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
EP0347146B1 (en) * 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB8814352D0 (en) * 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8909560D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
US5290933A (en) * 1989-04-26 1994-03-01 Smithkline & French Laboratories Limited Phenylpyrimidone derivatives
US5166344A (en) * 1989-05-31 1992-11-24 Berlex Laboratories, Inc. Process for the preparation of imidazoquinoxalinones
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CA2095786A1 (en) * 1992-05-08 1993-11-09 Franco J. Vaccarino Method of stimulating appetite
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5726319A (en) * 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
WO1995006648A1 (en) * 1993-09-03 1995-03-09 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivative
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
GB9407715D0 (en) * 1994-04-19 1994-06-15 British American Tobacco Co Improvements relating to tobacco smoke filter elements
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
WO1996026940A1 (fr) * 1995-03-01 1996-09-06 Kyowa Hakko Kogyo Co., Ltd. Derives d'imidazoquinazoline
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1997022367A1 (en) * 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP3514774B2 (ja) * 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.

Also Published As

Publication number Publication date
EP1312363A1 (en) 2003-05-21
PL356364A1 (en) 2003-04-07
US20030105114A1 (en) 2003-06-05
HU0203243D0 (pt) 2002-11-28
CA2405342A1 (en) 2003-03-28
KR20030027865A (ko) 2003-04-07
HUP0203243A2 (en) 2008-03-28
CN1410059A (zh) 2003-04-16
ZA200207677B (en) 2004-03-25
IL151835A0 (en) 2003-04-10
JP2003160508A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
BR0203886A (pt) Métodos de tratamento e kits compreendendo um secretagogo do hormÈnio do crescimento
NO990001L (no) Fremstilling og bruk av Radium-223 ved behandling av forkalket vev i forbindelse med smertelindring, ved benkreft og behandling av benoverflaten
WO2004069335A3 (en) Magnetic implants to treat body tissue structures
MXPA03001858A (es) Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
TW200509968A (en) Prevention and treatment of synucleinopathic disease
ATE375756T1 (de) Implantierbare schlinge
WO2003000336A3 (en) Magnetic therapy devices and methods
BRPI0414984A (pt) dispositivo de implante peniano, kit do mesmo, e, métodos para produzir um dispositivo de implante peniano e para implantar uma prótese peniana de um dispositivo de implante peniano no pênis de um paciente para o tratamento da impotência
MY164077A (en) Compositions and uses of et743 for treating cancer
EA200300560A1 (ru) Улучшенный способ лечения
EP1166778A3 (en) The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
EP1150698A4 (en) USES OF THE ENDOTHELIAL VASCULAR GROWTH FACTOR FOR THE TREATMENT OF DYSERECTION
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
EP0841056A3 (en) Personal clothing with effects caused by weak electromagnetic waves
RU2033119C1 (ru) Способ стимуляции эрогенных зон у женщин во время полового акта
RU2090151C1 (ru) Способ стимуляции эрогенных зон у женщины во время полового акта
RU2099017C1 (ru) Способ стимуляции эрогенных зон женщины во время полового акта
IL313846A (en) Tlr7/8-antagonist for the treatment of sjögren's syndrome or mixed connective tissue disease
胡智慧 et al. Study on the Interrelation between Auricular Good Conduction Point Stimulation and the Therapeutic Effect
RU2100011C1 (ru) Способ стимуляции эрогенных зон у женщин во время полового акта
KR200234697Y1 (ko) 남성성기배면지주물
田丽颖 Influence of electroacupuncture on artificial abortion-induced side effects

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1980 DE 16/12/2008.